242 related articles for article (PubMed ID: 29312553)
1. Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.
Mitwasi N; Feldmann A; Bergmann R; Berndt N; Arndt C; Koristka S; Kegler A; Jureczek J; Hoffmann A; Ehninger A; Cartellieri M; Albert S; Rossig C; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2017 Dec; 8(65):108584-108603. PubMed ID: 29312553
[TBL] [Abstract][Full Text] [Related]
2. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.
Albert S; Arndt C; Feldmann A; Bergmann R; Bachmann D; Koristka S; Ludwig F; Ziller-Walter P; Kegler A; Gärtner S; Schmitz M; Ehninger A; Cartellieri M; Ehninger G; Pietzsch HJ; Pietzsch J; Steinbach J; Bachmann M
Oncoimmunology; 2017; 6(4):e1287246. PubMed ID: 28507794
[TBL] [Abstract][Full Text] [Related]
3. Retargeting of UniCAR T cells with an
Bachmann D; Aliperta R; Bergmann R; Feldmann A; Koristka S; Arndt C; Loff S; Welzel P; Albert S; Kegler A; Ehninger A; Cartellieri M; Ehninger G; Bornhäuser M; von Bonin M; Werner C; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2018 Jan; 9(7):7487-7500. PubMed ID: 29484126
[TBL] [Abstract][Full Text] [Related]
4. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".
Feldmann A; Arndt C; Bergmann R; Loff S; Cartellieri M; Bachmann D; Aliperta R; Hetzenecker M; Ludwig F; Albert S; Ziller-Walter P; Kegler A; Koristka S; Gärtner S; Schmitz M; Ehninger A; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2017 May; 8(19):31368-31385. PubMed ID: 28404896
[TBL] [Abstract][Full Text] [Related]
5. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.
Arndt C; Feldmann A; Koristka S; Schäfer M; Bergmann R; Mitwasi N; Berndt N; Bachmann D; Kegler A; Schmitz M; Puentes-Cala E; Soto JA; Ehninger G; Pietzsch J; Liolios C; Wunderlich G; Kotzerke J; Kopka K; Bachmann M
Oncoimmunology; 2019; 8(11):1659095. PubMed ID: 31646084
[TBL] [Abstract][Full Text] [Related]
6. Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.
Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Máthé D; Hegedüs N; Szigeti K; Videira PA; Bachmann M; Arndt C
J Exp Clin Cancer Res; 2020 May; 39(1):77. PubMed ID: 32370811
[TBL] [Abstract][Full Text] [Related]
7. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP
Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241
[TBL] [Abstract][Full Text] [Related]
8. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
[TBL] [Abstract][Full Text] [Related]
9. Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab
Jureczek J; Feldmann A; Bergmann R; Arndt C; Berndt N; Koristka S; Loureiro LR; Mitwasi N; Hoffmann A; Kegler A; Bartsch T; Bachmann M
Onco Targets Ther; 2020; 13():5515-5527. PubMed ID: 32606767
[TBL] [Abstract][Full Text] [Related]
10. An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells.
Jureczek J; Bergmann R; Berndt N; Koristka S; Kegler A; Puentes-Cala E; Soto JA; Arndt C; Bachmann M; Feldmann A
Sci Rep; 2019 Jul; 9(1):10547. PubMed ID: 31332252
[TBL] [Abstract][Full Text] [Related]
11. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.
Pfeifer Serrahima J; Zhang C; Oberoi P; Bodden M; Röder J; Arndt C; Feldmann A; Kiefer A; Prüfer M; Kühnel I; Tonn T; Bachmann M; Wels WS
Cancer Immunol Immunother; 2023 Sep; 72(9):2905-2918. PubMed ID: 36688995
[TBL] [Abstract][Full Text] [Related]
12. From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells
Albert S; Arndt C; Koristka S; Berndt N; Bergmann R; Feldmann A; Schmitz M; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2018 May; 9(39):25597-25616. PubMed ID: 29876011
[TBL] [Abstract][Full Text] [Related]
13. The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells.
Bachmann M
Immunol Lett; 2019 Jul; 211():13-22. PubMed ID: 31091431
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
Meyer JE; Loff S; Dietrich J; Spehr J; Jurado Jiménez G; von Bonin M; Ehninger G; Cartellieri M; Ehninger A
Oncoimmunology; 2021; 10(1):1945804. PubMed ID: 34290907
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR).
Mitwasi N; Arndt C; Loureiro LR; Kegler A; Fasslrinner F; Berndt N; Bergmann R; Hořejší V; Rössig C; Bachmann M; Feldmann A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563312
[TBL] [Abstract][Full Text] [Related]
16. FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
Peschke JC; Bergmann R; Mehnert M; Gonzalez Soto KE; Loureiro LR; Mitwasi N; Kegler A; Altmann H; Wobus M; Máthé D; Szigeti K; Feldmann A; Bornhäuser M; Bachmann M; Fasslrinner F; Arndt C
Br J Haematol; 2023 Sep; 202(6):1137-1150. PubMed ID: 37460273
[TBL] [Abstract][Full Text] [Related]
17. UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells.
Arndt C; Loureiro LR; Feldmann A; Jureczek J; Bergmann R; Máthé D; Hegedüs N; Berndt N; Koristka S; Mitwasi N; Fasslrinner F; Lamprecht C; Kegler A; Hoffmann A; Bartsch T; Köseer AS; Egan G; Schmitz M; Hořejší V; Krause M; Dubrovska A; Bachmann M
Oncoimmunology; 2020; 9(1):1743036. PubMed ID: 32426176
[TBL] [Abstract][Full Text] [Related]
18. Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment.
Loureiro LR; Hoffmann L; Neuber C; Rupp L; Arndt C; Kegler A; Kubeil M; Hagemeyer CE; Stephan H; Schmitz M; Feldmann A; Bachmann M
J Exp Clin Cancer Res; 2023 Dec; 42(1):341. PubMed ID: 38102692
[TBL] [Abstract][Full Text] [Related]
19. T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression.
Kegler A; Koristka S; Bergmann R; Berndt N; Arndt C; Feldmann A; Hoffmann A; Bornhäuser M; Schmitz M; Bachmann MP
Oncoimmunology; 2019; 8(9):e1621676. PubMed ID: 31428518
[TBL] [Abstract][Full Text] [Related]
20. Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.
Loff S; Dietrich J; Meyer JE; Riewaldt J; Spehr J; von Bonin M; Gründer C; Swayampakula M; Franke K; Feldmann A; Bachmann M; Ehninger G; Ehninger A; Cartellieri M
Mol Ther Oncolytics; 2020 Jun; 17():408-420. PubMed ID: 32462078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]